Pingnan Xiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Pingnan Xiao has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Anne-Sofie Johansson
Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
2 shared publications- Hong Qian
Center for Hematology and Regenerative Medicine (HERM), Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden
2 shared publications - Julian Walfridsson
Center for Hematology and Regenerative Medicine Huddinge, Karolinska Institutet
2 shared publications Lakshmi Sandhow
Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
2 shared publications- Makoto Kondo
Cell Sheet Tissue Engineering Center, Department of Molecular Pharmaceutics, Health Sciences, The University of Utah, Utah, USA
2 shared publications - Mikael Sigvardsson
Division of Molecular Hematology, Lund University, Lund, Sweden
2 shared publications
Latest Publications
- 26 June 2018
- Published by American Society of Hematology in Blood Advances
- Vol. 2 (12) , 1480-1494
Distinct roles of mesenchymal stem and progenitor cells during the development of acute myeloid leukemia in mice
Despite increasing evidence for the involvement of bone marrow (BM) hematopoietic stem cell niche in leukemogenesis, how BM mesenchymal stem and progenitor cells (MSPCs) contribute to leukemia niche formation and progression remains unclear. Using an MLL-AF9 acute myeloid leukemia (AML) mouse model, we demonstrate dynamic alterations of BM cellular niche components, including MSPCs and endothelial cells during AML development and its association with AML engraftment. Primary patient AML cells also induced similar niche alterations in xenografted mice. AML cell infiltration in BM causes an expansion of early B-cell factor 2+ (Ebf2+) MSPCs with reduced Cxcl12 expression and enhanced generation of more differentiated mesenchymal progenitor cells. Importantly, in vivo fate-mapping indicates that Ebf2+ MSPCs participated in AML niche formation. Ebf2+ cell deletion accelerated the AML development. These data suggest that native BM MSPCs may suppress AML. However, they can be remodeled by AML cells to form leukemic niche that might contribute to AML progression. AML induced dysregulation of hematopoietic niche factors like Angptl1, Cxcl12, Kitl, Il6, Nov, and Spp1 in AML BM MSPCs, which was associated with AML engraftment and partially appeared before the massive expansion of AML cells, indicating the possible involvement of the niche factors in AML progression. Our study demonstrates distinct dynamic features and roles of BM MSPCs during AML development. Key Points MLL-AF9 AML cell–induced BM niche alteration is correlated with leukemia burden. Ebf2+ MSPCs participate in AML niche formation, and Ebf2+ cell depletion accelerates AML development. Visual Abstract
- 26 June 2018
- Published by American Society of Hematology in Blood Advances
- Vol. 2 (12) , 1480-1494
Distinct roles of mesenchymal stem and progenitor cells during the development of acute myeloid leukemia in mice
Despite increasing evidence for the involvement of bone marrow (BM) hematopoietic stem cell niche in leukemogenesis, how BM mesenchymal stem and progenitor cells (MSPCs) contribute to leukemia niche formation and progression remains unclear. Using an MLL-AF9 acute myeloid leukemia (AML) mouse model, we demonstrate dynamic alterations of BM cellular niche components, including MSPCs and endothelial cells during AML development and its association with AML engraftment. Primary patient AML cells also induced similar niche alterations in xenografted mice. AML cell infiltration in BM causes an expansion of early B-cell factor 2+ (Ebf2+) MSPCs with reduced Cxcl12 expression and enhanced generation of more differentiated mesenchymal progenitor cells. Importantly, in vivo fate-mapping indicates that Ebf2+ MSPCs participated in AML niche formation. Ebf2+ cell deletion accelerated the AML development. These data suggest that native BM MSPCs may suppress AML. However, they can be remodeled by AML cells to form leukemic niche that might contribute to AML progression. AML induced dysregulation of hematopoietic niche factors like Angptl1, Cxcl12, Kitl, Il6, Nov, and Spp1 in AML BM MSPCs, which was associated with AML engraftment and partially appeared before the massive expansion of AML cells, indicating the possible involvement of the niche factors in AML progression. Our study demonstrates distinct dynamic features and roles of BM MSPCs during AML development. Key Points MLL-AF9 AML cell–induced BM niche alteration is correlated with leukemia burden. Ebf2+ MSPCs participate in AML niche formation, and Ebf2+ cell depletion accelerates AML development. Visual Abstract
- 7 March 2018
- Published by American Society of Hematology in Blood Advances
- Vol. 2 (5) , 534-548
Sipa1 deficiency–induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm
Key Points: Sipa1 loss leads to BM niche alterations prior to the initiation of MPN. Sipa1-deficient BM niche induces lethal MPN from normal hematopoietic cells.
- 7 March 2018
- Published by American Society of Hematology in Blood Advances
- Vol. 2 (5) , 534-548
Sipa1 deficiency–induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm
Key Points: Sipa1 loss leads to BM niche alterations prior to the initiation of MPN. Sipa1-deficient BM niche induces lethal MPN from normal hematopoietic cells.